Skip to main content
. Author manuscript; available in PMC: 2009 Oct 15.
Published in final edited form as: Cancer Res. 2008 Oct 15;68(20):8286–8294. doi: 10.1158/0008-5472.CAN-07-6316

Figure 3.

Figure 3

ErbB2 (+) human tumors display reduced LRIG1 expression. A, Lysates of ErbB2 (+) tumors and patient-matched normal samples were immunoblotted with antibodies to ErbB2, LRIG1, and actin. A pie chart depicting the frequency of LRIG1 loss in these tumors is shown below. B, The Hess study available through Oncomine (27) was queried for transcript expression of LRIG1 in breast tumors and is plotted on the basis of ErbB2 status of the tumors.